Impact of intratumoral expression levels of fluoropyrimidine-Metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Kim, Ji Yeon ^a   Shin, Eun ^a   Kim, Jin Won ^a   Lee, Hye Seung ^a   Lee, Dae Won ^a   Kim, Se Hyun ^a   Lee, Jeong Ok ^a   Kim, Yu Jung ^a   Kim, Jee Hyun ^a   Bang, Soo Mee ^a   Ahn, Sang Hoon ^a   Park, Do Joong ^a   Lee, Jong Seok ^a   Lee, Ju Seog ^b   Kim, Hyung Ho ^a   Lee, Keun Wook ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; ENZYME METABOLISM; FEMALE; GASTRECTOMY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; DRUG COMBINATION; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DRUG COMBINATIONS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OXONIC ACID; PROGNOSIS; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 84925729460     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120324     Document Type: Article

References (32)

1. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4 PMID: 22226517
2. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011; 29(33):4387-93. doi: 10.1200/JCO.2011.36.5908 PMID: 22010012
3. Kim YH. Chemotherapy for advanced gastric cancer: slow but further progress. Cancer Res Treat. 2005; 37(2):79-86. doi: 10.4143/crt.2005.37.2.79 PMID: 19956484
4. Kim SJ, Kim YJ, Kim JH, Park do J, Kim HH, Lee JS, et al. Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer. Cancer science. 2013; 104(1):116-23. doi: 10.1111/cas.12044 PMID: 23066919
5. Kim N, Park C, Park DJ, Kim HH, Kim S, Kim YJ, et al. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy. Ann Oncol. 2012; 23(8):2065-71. doi: 10.1093/annonc/mds106 PMID: 22589332
6. Jeong JH, Ryu MH, Ryoo BY, Lee SS, Park I, Lee SH, et al. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer. Cancer chemotherapy and pharmacology. 2012; 70(4):523-9. PMID: 22864947
7. Choi IS, Lee HS, Lee KW, Kim H, Kim KH, Kim YJ, et al. Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes. Medical oncology. 2011; 28(4):991-8. doi: 10.1007/ s12032-010-9590-4 PMID: 20533001
8. Jeung HC, Rha SY, Shin SJ, Lim SJ, Roh JK, Noh SH, et al. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anti-cancer drugs. 2011; 22(8):801-10. doi: 10.1097/CAD.0b013e328345c9ae PMID: 21572321
9. Takiuchi H, Kawabe S, Gotoh M, Katsu K. Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. Gastrointestinal cancer research: GCR. 2007; 1(5):171-6. PMID: 19262706
10. nd English Edition. Gastric Cancer. 1998; 1(1):10-24. PMID: 11957040
11. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. European journal of cancer. 1994; 30A(10):1517-22. PMID: 7833111
12. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, et al. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res. 1999; 5(4):883-9. PMID: 10213225
13. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Kashiwaba M, et al. Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J Cancer Res. 2002; 93(12):1342-50. PMID: 12495474
14. Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, et al. A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Lung cancer. 2013; 79(1):27-32. doi: 10.1016/j.lungcan.2012.09.013 PMID: 23079156
15. Fukuda H, Takiguchi N, Koda K, Oda K, Seike K, Miyazaki M. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer investigation. 2006; 24(3):235-41. PMID: 16809149
16. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, et al. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res. 2000; 91(1):105-12. PMID: 10744051
17. Takabayashi A, Iwata S, Kawai Y, Kanai M, Taki Y, Takechi T, et al. Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy. International journal of oncology. 2000; 17(5):889-95. PMID: 11029488
18. Terashima M, Fujiwara H, Takagane A, Abe K, Irinoda T, Nakaya T, et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer. 2003; 6 Suppl 1:71-81. PMID: 12775024
19. Oeda M, Yoshida K, Sanada Y, Wada Y, Suzuki T, Mizuiri H, et al. The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance. Oncology reports. 2006; 16(6):1165-72. PMID: 17089033
20. Toriumi F, Kubota T, Saikawa Y, Yoshida M, Otani Y, Watanabe M, et al. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer research. 2004; 24(4):2455-63. PMID: 15330198
21. Koizumi W, Okayasu I, Hyodo I, Sakamoto J, Kojima H, Clinical Study Group of C. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anti-cancer drugs. 2008; 19(8):819-24. doi: 10.1097/CAD. 0b013e3283094b5d PMID: 18690094
22. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-cancer drugs. 1996; 7(5):548-57. PMID: 8862723
23. Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, et al. Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection. Journal of surgical oncology. 2011; 104(2):146-54. doi: 10.1002/jso.21955 PMID: 21538357
24. Kuramochi H, Hayashi K, Uchida K, Nakajima G, Hatori T, Danenberg KD, et al. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer chemotherapy and pharmacology. 2008; 63(1):85-9. doi: 10.1007/s00280-008-0714-x PMID: 18309485
25. Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, et al. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. International journal of cancer. 2006; 119(8):1927-33. PMID: 16736497
26. Miyamoto S, Boku N, Ohtsu A, Yoshida S, Ochiai A, Okabe H, et al. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. International journal of oncology. 2000; 17(4):653-8. PMID: 10995874
27. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Nakaya T, et al. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity. European journal of cancer. 2003; 39(16):2387-94. PMID: 14556932
28. Shimizu T, Yamada Y, Yasui H, Shirao K, Fukuoka M. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine. Anticancer research. 2005; 25(4):2997-3001. PMID: 16080558
29. Ide H, Kikuchi E, Hasegawa M, Kozakai N, Kosaka T, Miyajima A, et al. Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma. BMC cancer. 2012; 12:420. doi: 10.1186/1471-2407-12-420 PMID: 22998564
30. Kim JY, Shin E, Kim JW, Lee HS, Kim YJ, Kim JH, et al. Impact of the expression levels of fluoropyrimidine pathway genes on treatment outcomes from adjuvant S-1 therapy in gastric cancer. Ann Oncol. 2014; 25((suppl-4)):iv210-iv53 (647P).
31. Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, et al. Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. Gastric Cancer. 2014.
32. Cui Y, Li Q, Yu Y, Chen Y, Feng Y, Wang Y, et al. Combination of low-dose docetaxel and standarddose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. Cancer chemotherapy and pharmacology. 2013; 71(1):145-52. doi: 10.1007/s00280-012-1991-y PMID: 23064955